{"id":"decitabine-cedazuridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, thrombocytopenia, neutropenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a cytidine analog that incorporates into DNA and inhibits DNA methyltransferase (DNMT), reducing aberrant DNA methylation in cancer cells. This hypomethylating effect reactivates epigenetically silenced genes, including tumor suppressors, and promotes cell differentiation and apoptosis. Cedazuridine is a cytidine deaminase inhibitor that increases decitabine bioavailability by preventing its degradation, allowing for oral administration instead of intravenous infusion.","oneSentence":"Decitabine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA, leading to reactivation of silenced tumor suppressor genes and differentiation of myelodysplastic cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:54.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndromes (MDS)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT06661915","phase":"PHASE2","title":"A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-14","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia","enrollment":62},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT04340843","phase":"PHASE2","title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-08","conditions":"Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma","enrollment":19},{"nctId":"NCT05272384","phase":"PHASE1","title":"Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-03","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT06672146","phase":"PHASE2","title":"Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-16","conditions":"Acute Myeloid Leukemia","enrollment":93},{"nctId":"NCT07437950","phase":"PHASE2","title":"Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-14","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT06577441","phase":"PHASE2","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-12","conditions":"Myelodysplastic Syndrome","enrollment":54},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT05960773","phase":"PHASE2","title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-31","conditions":"Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma","enrollment":9},{"nctId":"NCT04742634","phase":"PHASE1, PHASE2","title":"Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-05-12","conditions":"Myelodysplastic Syndromes","enrollment":209},{"nctId":"NCT05636514","phase":"PHASE1","title":"Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT07472322","phase":"PHASE1, PHASE2","title":"ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV","enrollment":31},{"nctId":"NCT06484062","phase":"PHASE1","title":"Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT04746235","phase":"PHASE2","title":"Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT03502668","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2018-07-27","conditions":"Myelodysplastic Syndromes","enrollment":160},{"nctId":"NCT04953897","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-12-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":18},{"nctId":"NCT04953910","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2022-12-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":27},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm","enrollment":27},{"nctId":"NCT06297629","phase":"PHASE2","title":"A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-01","conditions":"Allogeneic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT04061421","phase":"PHASE1, PHASE2","title":"Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)","status":"RECRUITING","sponsor":"Michael Savona","startDate":"2021-11-24","conditions":"MDS/MPN","enrollment":94},{"nctId":"NCT05403450","phase":"PHASE1","title":"A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-02-22","conditions":"Relapsed/Refractory Peripheral T-cell Lymphoma","enrollment":33},{"nctId":"NCT05010122","phase":"PHASE1, PHASE2","title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT05007873","phase":"PHASE2","title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":70},{"nctId":"NCT06191978","phase":"PHASE1","title":"A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-07","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT04655755","phase":"PHASE1, PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-19","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT06284460","phase":"PHASE1, PHASE2","title":"Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-31","conditions":"Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm","enrollment":""},{"nctId":"NCT04872543","phase":"PHASE2","title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-29","conditions":"Malignant Peripheral Nerve Sheath Tumors (MPNST)","enrollment":25},{"nctId":"NCT06177171","phase":"PHASE1","title":"Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors","status":"RECRUITING","sponsor":"Pamela Munster","startDate":"2024-02-07","conditions":"BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation","enrollment":18},{"nctId":"NCT06091267","phase":"PHASE1, PHASE2","title":"PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Beijing Research Institute","startDate":"2023-10-16","conditions":"Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT03875287","phase":"PHASE1","title":"Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-17","conditions":"Solid Tumor","enrollment":35},{"nctId":"NCT05799079","phase":"PHASE2","title":"Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant","status":"TERMINATED","sponsor":"Sanjay Mohan","startDate":"2023-04-13","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT06327685","phase":"PHASE1","title":"Avapritinib With Decitabine in Patients With SM-AHN","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-13","conditions":"Systemic Mastocytosis With an Associated Hematologic Neoplasm","enrollment":34},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT03613532","phase":"PHASE1","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2018-10-24","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":102},{"nctId":"NCT04245397","phase":"PHASE1","title":"Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2020-06-30","conditions":"Myelodysplastic Syndromes","enrollment":151},{"nctId":"NCT03922555","phase":"PHASE1","title":"ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-07-12","conditions":"Neurological Cancer","enrollment":18},{"nctId":"NCT04657081","phase":"PHASE1, PHASE2","title":"Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-02-09","conditions":"Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT05089370","phase":"PHASE1, PHASE2","title":"Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-06-20","conditions":"Malignant Melanoma","enrollment":8},{"nctId":"NCT05918055","phase":"PHASE1, PHASE2","title":"Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-14","conditions":"Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT05178693","phase":"PHASE1","title":"Lutathera and ASTX727 in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-04-25","conditions":"Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT05037500","phase":"PHASE1","title":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2022-01-26","conditions":"Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":8},{"nctId":"NCT04817241","phase":"PHASE1, PHASE2","title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-10","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT04774393","phase":"PHASE1, PHASE2","title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-24","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":84},{"nctId":"NCT04093570","phase":"PHASE2","title":"A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)","status":"ENROLLING_BY_INVITATION","sponsor":"Taiho Oncology, Inc.","startDate":"2019-09-30","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes","enrollment":332},{"nctId":"NCT04975919","phase":"PHASE2","title":"Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-29","conditions":"Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia","enrollment":20},{"nctId":"NCT06445959","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-29","conditions":"Mutant IDH1 Inhibitor Olutasidenib","enrollment":78},{"nctId":"NCT05360160","phase":"PHASE1, PHASE2","title":"A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-10-14","conditions":"Acute Myeloid Leukemia","enrollment":43},{"nctId":"NCT05396859","phase":"PHASE1","title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-10-28","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT04878432","phase":"PHASE2","title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-17","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":39},{"nctId":"NCT05148234","phase":"PHASE1, PHASE2","title":"BMS-986253 in Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-29","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT02998567","phase":"PHASE1","title":"Combination Study of Guadecitabine/ASTX727 and Pembrolizumab","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-01-26","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04980404","phase":"PHASE1","title":"Inqovi Maintenance Therapy in Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-09-17","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia","enrollment":22},{"nctId":"NCT06778187","phase":"PHASE2","title":"Oral-ATO for TP53-mutated Myeloid Malignancies","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-02-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT04857645","phase":"PHASE2","title":"ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2021-06-22","conditions":"MDS, AML","enrollment":57},{"nctId":"NCT06802146","phase":"EARLY_PHASE1","title":"Early Intervention in High Risk CCUS","status":"RECRUITING","sponsor":"Lachelle D. Weeks, MD, PhD","startDate":"2025-02-07","conditions":"Clonal Cytopenia of Undetermined Significance, Cytopenia","enrollment":108},{"nctId":"NCT06351306","phase":"PHASE2","title":"DEC-C and Thioguanine for R/R AML","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-04-01","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05883956","phase":"PHASE3","title":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Australia Pharmaceutical Pty Ltd","startDate":"2023-12-20","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic","enrollment":13},{"nctId":"NCT03906695","phase":"PHASE1","title":"Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-03-15","conditions":"Lower-risk Myelodysplastic","enrollment":30},{"nctId":"NCT02649790","phase":"PHASE1, PHASE2","title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":277},{"nctId":"NCT06113289","phase":"PHASE1, PHASE2","title":"A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05835011","phase":"PHASE2","title":"A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)","status":"TERMINATED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2023-06-27","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT03306264","phase":"PHASE3","title":"Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2018-02-15","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":227},{"nctId":"NCT02103478","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2014-10-28","conditions":"Myelodysplastic Syndrome, MDS","enrollment":130},{"nctId":"NCT04155580","phase":"PHASE1","title":"A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2020-06-12","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT03813186","phase":"PHASE1","title":"Effect of Food on Blood Levels of ASTX727","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2018-11-08","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT06357858","phase":"PHASE1","title":"ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-06-01","conditions":"Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04134884","phase":"PHASE1","title":"Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Kathy Miller","startDate":"2020-04-01","conditions":"Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor","enrollment":34},{"nctId":"NCT05456269","phase":"PHASE1","title":"A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS","status":"WITHDRAWN","sponsor":"Race Oncology Ltd","startDate":"2022-07-29","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04985656","phase":"PHASE2","title":"A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2021-10-01","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":""},{"nctId":"NCT04013880","phase":"PHASE1, PHASE2","title":"ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2019-08-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"ANGIOEDEMA"},{"count":1,"reaction":"CERVICAL VERTEBRAL FRACTURE"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"INCREASED UPPER AIRWAY SECRETION"},{"count":1,"reaction":"LUMBAR VERTEBRAL FRACTURE"},{"count":1,"reaction":"MOBILITY DECREASED"},{"count":1,"reaction":"PLASMA CELL MYELOMA"},{"count":1,"reaction":"RED BLOOD CELL COUNT DECREASED"},{"count":1,"reaction":"SPEECH DISORDER"}],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ASTX727","INQOVI"],"phase":"phase_3","status":"active","brandName":"Decitabine/Cedazuridine","genericName":"Decitabine/Cedazuridine","companyName":"Astex Pharmaceuticals, Inc.","companyId":"astex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA, leading to reactivation of silenced tumor suppressor genes and differentiation of myelodysplastic cells. Used for Myelodysplastic syndromes (MDS), Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}